Abstract
Background COVID-19 caused by severe acute respiratory syndrome coronavirus 2 appeared in December 2019 in Wuhan, China.
Objective We aimed to investigate the clinical manifestation include signs and symptoms, laboratory results, and perinatal outcomes in pregnant women with COVID-19.
Materials and Methods We searched PubMed via LitCovid hub, Embase, Scopus, Web of sciences, and Google scholar on 07 April 2020. Meta-analysis was performed via CMA software using the Mantel-Haenszel method. The event rate with 95% CI was calculated for each variable.
Results Ten studies were selected. The pooled prevalence for fever, post-partum fever, cough, myalgia, fatigue, dyspnea, sore throat, and diarrhea were 66.8 %, 37.1 %, 35.5 %, 24.6 %, 14.9%, 14.6 %, 11.5%, and 7.6 %, respectively. Laboratory test results were 49.8 % for lymphopenia, 47.7 % for leukocytosis, 83.7 % for elevated neutrophil ratio, 57 % for elevated C-reactive protein, and 71.4 % for decreased lymphocyte ratio. The rate of cesarean section for delivery in all cases was 84%. Only one case was the newborn of a mother with COVID-19 positive. Also, there was only one death due to Decreased lymphocyte ratio.
Conclusion Fever was the most common signs and symptoms in pregnant women with COVID-19. Among the laboratory tests, the highest amount was related to elevated neutrophil ratio. It seems that due to the differences between pregnant women and the general population, special measures should be considered to treat these patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Not find
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
this study is a systematic review
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
there is not data available
